Facet Biotech
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Facet Biotech sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
Facet Biotech: 13 sponsored US clinical trials, none currently recruiting.
Facet Biotech sponsors 13 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 0 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Graft Vs Host Disease, with 1 trials.
Top-decile sponsor footprint
Facet Biotech ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
10 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
13 total, page 1 of 1
A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
NCT00516841
Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma
NCT00425347
Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study
NCT00279435
A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
NCT00279422
Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease
NCT00267722
Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease
NCT00267709
Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis
NCT00267306
Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis
NCT00073047
Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease
NCT00032292
Research Study in Patients With Severe Ulcerative Colitis
NCT00032305
A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease
NCT00072943
Study of Daclizumab in Patients With Chronic, Persistent Asthma
NCT00028288
Pilot Study in Patients With Symptomatic Steroid-Naive Asthma
NCT00024544
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 10 |
Therapeutic Areas
How the Facet Biotech early-phase archive is shaped
13 indexed studies, none listed as recruiting (0% open); 10 completed (77%).
Phase mix: 0 late (III/IV) vs 13 early (I/II) (early-phase heavy).
Top condition: Graft Vs Host Disease (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Facet Biotech: archived-pipeline peers nationwide
Peers matched on 13 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Facet Biotech sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 archived trials
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Facet Biotech page
13 registered trials is a research-attention snapshot, not an endorsement of Facet Biotech or any single study.
- None of Facet Biotech's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Graft Vs Host Disease is the condition Facet Biotech studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Graft Vs Host Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Facet Biotech pipeline card: 13 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.